ROCKET PHARMACEUTICALS, INC. — Form 10-Q
Filed August 10, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 72/100
What the filing says
Rocket Pharmaceuticals sold a Priority Review Voucher (PRV BLA 125806) issued for KRESLADI (marnetegragene autotemcel), approved March 26, 2026, for pediatric LAD-I treatment, to an undisclosed limited company for $180,000,000 cash at closing. The PRV enables FDA priority review of a future drug application. Rocket retains post-closing obligations including marketing the approved product within 365 days and complying with FDA regulations; buyer assumes only the priority review fee and other standard holder fees.
Why this rating
$180M is 85% of Rocket's $212.5M market cap—a material liquidity event. PRV sales are non-core but the proceeds significantly strengthen cash position. Upside: near-term funding relief for a development-stage biotech. Downside: loss of valuable FDA priority benefit asset. High relative to company size; moderate absolute strategic impact.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.